3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
durvalumab
9
Bevacizumab
8
tremelimumab
4
lenvatinib
3
atezolizumab
3
Nivolumab
3
Ipilimumab
3
fludarabine
2
Magnetic Resonance Imaging
2
Hepatectomy
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
trastuzumab deruxtecan
1
toripalimab
1
ropidoxuridine
1
poly ICLC
1
pembrolizumab
1
brodalumab
1
X-Rays
1
Whole Genome Sequencing
1
Technetium Tc 99m Aggregated Albumin
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiosurgery
1
Radionuclide Imaging
1
Pregabalin
1
Pluvicto
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Erlotinib Hydrochloride
×
90 days
×
Clear all
No trials found.